KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Discontinued OperationsCash from Discontinued OperationsCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryDepreciation & Amortization (CF)Depreciation & Amortization (CF)DivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables Refunds
Ratios

BioNTech SE (BNTX) Long-Term Debt Issuances (2018 - 2025)

BioNTech SE (BNTX) posted Long-Term Debt Issuances of $7.8 million for Q4 2025, up 3524.32% on a QoQ basis from $215188.0 in Q4 2023.

BioNTech SE (BNTX) has 6 years of Long-Term Debt Issuances data on file, last reported at $7.8 million in Q4 2025.

  • In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $7.8 million; the TTM figure through Dec 2025 stood at $8.3 million (changed N/A YoY), while the FY2025 annual figure was $7.6 million, changed N/A from the prior year.
  • Long-Term Debt Issuances advanced to $7.8 million in Q4 2025, from $215188.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $7.8 million in Q4 2025 and bottomed at $108859.0 in Q3 2023.
  • A 3-year average of $1.5 million and a median of $214299.7 in 2023 frame the typical range for Long-Term Debt Issuances.
  • The widest YoY moves for Long-Term Debt Issuances: up 5.46% in 2023, down 73.01% in 2023.
  • Year by year, Long-Term Debt Issuances stood at $204049.5 in 2022, then increased by 5.46% to $215188.0 in 2023, then surged by 3524.32% to $7.8 million in 2025.
  • The last three Long-Term Debt Issuances figures came in at $7.8 million (Q4 2025), $215188.0 (Q4 2023), and $108859.0 (Q3 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Issuances (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 2.73 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 BioNTech SE 27.66 Bn 7.53 Bn 668.28 Mn 7.80 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 7.80 Mn
Dec 31, 2025 7.80 Mn
Dec 31, 2023 215,187.98
Dec 31, 2023 215,187.98
Sep 30, 2023 108,859.05
Sep 30, 2023 108,859.05
Dec 31, 2022 204,049.47
Dec 31, 2022 204,049.47
Sep 30, 2022 403,309.73
Sep 30, 2022 403,309.73
Jun 30, 2022 213,411.34
Jun 30, 2022 213,411.34
Dec 31, 2020 63.91
Dec 31, 2020 63.91
Mar 31, 2020 3.20 Mn
Mar 31, 2020 3.20 Mn
Dec 31, 2019 3.25 Mn
Dec 31, 2019 3.25 Mn
Dec 31, 2018 -2.85 Mn
Dec 31, 2018 -2.85 Mn